Literature DB >> 6706043

Roles of chlorpropamide, alcohol and acetaldehyde in determining the chlorpropamide-alcohol flush.

L Groop, C J Eriksson, R Huupponen, R Ylikahri, R Pelkonen.   

Abstract

The value and reproducibility of the chlorpropamide-alcohol flush (CPAF) have been questioned, and objective measures of the test are required. Recording of facial skin temperature, measurement of chlorpropamide, ethanol and acetaldehyde concentrations have been proposed for this purpose. The present study was designed to evaluate the relative contributions of these variables in determining CPAF. Twenty-one Type 2 (non-insulin-dependent) diabetic patients (11 CPAF-positive and 10 CPAF-negative according to previous tests with standard amounts of alcohol and chlorpropamide) were investigated in a random fashion with either chlorpropamide or placebo given on three subsequent evenings before a two-step alcohol challenge with increasing body-weight-matched amounts of alcohol. Higher rises in facial skin temperature and heart rate, higher flush-score and higher acetaldehyde levels resulted from chlorpropamide therapy than followed placebo. After smaller alcohol challenges (with chlorpropamide pretreatment) there were positive intercorrelations between flush-score, rise in facial skin temperature, and plasma concentrations of chlorpropamide and blood acetaldehyde. The increased alcohol dose abolished most of these correlations and a minimum temperature rise of 1.8 degrees C appeared in all but two subjects regardless of previous CPAF classification. During the current experimental conditions, the previously-classified CPAF-positive and CPAF-negative patients did not differ with respect to flush-score, rise in skin temperature, heart rate, blood acetaldehyde or ethanol concentrations, whereas they differed with respect to chlorpropamide concentrations. The present results support the view that CPAF is associated with elevated blood acetaldehyde levels due to inhibition of aldehyde dehydrogenase by chlorpropamide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6706043     DOI: 10.1007/bf00252260

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

1.  Alcohol sensitivity in diabetics receiving chlorpropromide.

Authors:  M G FITZGERALD; R GADDIE; J M MALINS
Journal:  Diabetes       Date:  1962 Jan-Feb       Impact factor: 9.461

2.  Chlorpropamide alcohol flush.

Authors:  D B Jefferys; H Keen; S Ng Tang Fui
Journal:  Lancet       Date:  1981-02-21       Impact factor: 79.321

3.  Is the blood chlorpropamide concentration critical in chlorpropamide alcohol flush?

Authors:  P Jerntorp; L O Almér; A Melander
Journal:  Lancet       Date:  1981-01-17       Impact factor: 79.321

4.  Chlorpropamide alcohol flushing and diabetic retinopathy.

Authors:  R D Leslie; A H Barnett; D A Pyke
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

5.  The determination of acetaldehyde in human blood by the perchloric acid precipitation method: the characterization and elimination of artefactual acetaldehyde formation.

Authors:  C J Eriksson; Y Mizoi; T Fukunaga
Journal:  Anal Biochem       Date:  1982-09-15       Impact factor: 3.365

6.  Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.

Authors:  P Jerntorp; L O Almér
Journal:  Acta Med Scand Suppl       Date:  1981

7.  Increase of plasma acetaldehyde. An objective indicator of the chlorpropamide alcohol flush.

Authors:  P Jerntorp; H Ohlin; B Bergström; L O Almér
Journal:  Diabetes       Date:  1981-09       Impact factor: 9.461

8.  Blood concentrations of acetaldehyde during chlorpropamide-alcohol flush.

Authors:  A H Barnett; C Gonzalez-Auvert; D A Pyke; J B Saunders; R Williams; C J Dickenson; M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-10

9.  Chlorpropamide and glibenclamide serum concentrations in hospitalized patients.

Authors:  R Huupponen; J Viikari; H Saarimaa
Journal:  Ann Clin Res       Date:  1982-06

10.  Chlorpropamide alcohol flush and circulating met-enkephalin: a positive link.

Authors:  S Medbak; J A Wass; V Clement-Jones; E D Cooke; S A Bowcock; A G Cudworth; L H Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-10
View more
  8 in total

Review 1.  Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.

Authors:  Kari A Mergenhagen; Bethany A Wattengel; Megan K Skelly; Collin M Clark; Thomas A Russo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  To flush or not to flush? Comments on the chlorpropamide-alcohol flush.

Authors:  W Waldhäusl
Journal:  Diabetologia       Date:  1984-01       Impact factor: 10.122

Review 4.  Comparative tolerability of sulphonylureas in diabetes mellitus.

Authors:  A D Harrower
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 5.  Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Authors:  R Huupponen
Journal:  Med Toxicol       Date:  1987 May-Jun

Review 6.  Comparative tolerability profiles of oral antidiabetic agents.

Authors:  A J Krentz; R E Ferner; C J Bailey
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 7.  Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.

Authors:  Ashutosh Ojha; Utkarsh Ojha; Raihan Mohammed; Abhinaya Chandrashekar; Harsh Ojha
Journal:  Clin Pharmacol       Date:  2019-05-09

8.  Sulfonylureas and their use in clinical practice.

Authors:  Daniele Sola; Luca Rossi; Gian Piero Carnevale Schianca; Pamela Maffioli; Marcello Bigliocca; Roberto Mella; Francesca Corlianò; Gian Paolo Fra; Ettore Bartoli; Giuseppe Derosa
Journal:  Arch Med Sci       Date:  2015-08-11       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.